Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 10, 2025

RadNet raises 2025 revenue guidance as advanced imaging volumes and digital health drive growth

View original at seekingalpha.com
RadNet raises 2025 revenue guidance as advanced imaging volumes and digital health drive growth Earnings Call Insights: RadNet, Inc. (RDNT) Q3 2025 MANAGEMENT VIEW * CEO Howard Berger opened by stating, "I am very pleased with the performance in the third quarter…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • EBCD payer adoption discussions are progressing positively with increasing traction, though large payers move slowly.

    80% confidence
  • RadNet needs more sales personnel post-iCAD acquisition, and margin expansion will increasingly be driven by digital health tools.

    80% confidence
  • Aggregate MRI volume increased 14.8%, CT volume increased 9.4%, and PET/CT volume increased 21.1% from Q3 2024.

    80% confidence
  • Exposure to Medicaid and health insurance exchanges is minimal, reducing risk from policy changes.

    80% confidence
  • Digital Health revenue increased 51.6% from Q3 2024, partially due to iCAD's revenue contribution since July 17 acquisition.

    80% confidence
  • PET/CT growth is driven by PSMA and amyloid brain studies, which now make up 20% of PET/CT volume.

    80% confidence
  • Advanced imaging volumes increased 13.0% on an aggregate basis and 9.9% on a same-center basis, driven by equipment upgrades, AI-driven scheduling, capacity expansion, and shift from hospital to ambulatory imaging.

    80% confidence
  • Virtual radiology is an inevitability, and DeepHealth serves as a platform to bundle and integrate multiple AI modules for both internal and external customers.

    80% confidence
  • iCAD contributed approximately $3.9 million in revenue during Q3 2025.

    80% confidence
  • Adjusted EBITDA margins increased by 26 basis points from 16% to 16.2% year-over-year.

    80% confidence
  • RadNet operates 407 centers as of September 30, 2025, with one new center opened during Q3 and 4.9% total same-center procedure volume growth.

    80% confidence
  • AI revenue within Digital Health, inclusive of iCAD revenue from ProFound AI and Deep Health solutions, increased 112% from Q3 2024.

    80% confidence
  • DSOs (Days Sales Outstanding) reduced to 31.9 days, the lowest historical level for RadNet.

    80% confidence
  • See-Mode's thyroid ultrasound technology achieved a 30% reduction in scan time across 240+ centers.

    80% confidence
  • TechLive rollout should be substantially complete by the end of 2025, and has reduced exam closure hours by about 42% relative to last year.

    80% confidence
  • Q3 2025 revenue and adjusted EBITDA were both quarterly records and exceeded internal budgets set at the beginning of 2025.

    80% confidence
  • Total company revenue increased 13.4% and adjusted EBITDA increased 15.2% relative to Q3 2024, resulting in a 26 basis point improvement in adjusted EBITDA margins.

    80% confidence
  • RadNet increased imaging center revenue guidance by $50 million at the low end and $30 million at the high end, and increased adjusted EBITDA guidance by $5 million at both ends.

    80% confidence
  • EBCD AI revenue rose 28.7% year-over-year.

    80% confidence
  • 2026 Medicare reimbursement changes will benefit RadNet with approximately $4-5 million revenue uplift on roughly $2 billion of revenue.

    80% confidence
  • Labor markets for radiology technologists remain challenging but have stabilized, and RadNet is seeing increasing inbound calls from health systems for partnership opportunities.

    80% confidence
  • Cash balance as of September 30, 2025 was $804.7 million with net debt to adjusted EBITDA ratio of approximately 1.0.

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
RadNet raises 2025 revenue guidance as advanced imaging volumes and digital health drive growth — Source | Via News | ViaNews Market